These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18398308)

  • 1. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations.
    Vidor E; Plotkin SA
    Hum Vaccin; 2008; 4(5):328-40. PubMed ID: 18398308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
    Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
    Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.
    Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C
    Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
    Blanchard Rohner G; Chatzis O; Chinwangso P; Rohr M; Grillet S; Salomon C; Lemaître B; Boonrak P; Lawpoolsri S; Clutterbuck E; Poredi IK; Wijagkanalan W; Spiegel J; Pham HT; Viviani S; Siegrist CA
    Clin Infect Dis; 2019 Mar; 68(7):1213-1222. PubMed ID: 30759183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
    Wood N; Marshall H; White OJ; Holt PG; McIntyre P
    Pediatr Infect Dis J; 2014 May; 33(5):511-7. PubMed ID: 24445839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
    Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
    J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.
    van der Lee S; Hendrikx LH; Sanders EAM; Berbers GAM; Buisman AM
    Front Immunol; 2018; 9():51. PubMed ID: 29416544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
    Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
    Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults.
    Schmitt HJ; Mohnike K; Zepp F; Herden P; Hosbach P
    Vaccine; 2000 Oct; 19(4-5):403-8. PubMed ID: 11027800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.